Amendment to Development and Marketing Agreement between Boehringer Ingelheim International GmbH and InterMune, Inc.
Contract Categories:
Business Finance
›
Modification Agreements
Summary
This letter agreement, dated May 28, 2002, amends the existing Development and Marketing Agreement between Boehringer Ingelheim International GmbH and InterMune, Inc. The amendment expands the scope of the agreement to include liver fibrosis as a covered field and new indication, and adds a specific clinical protocol (GILF-001) to the agreement. Both parties have agreed to these changes by signing the letter.
EX-10.53 10 a2082633zex-10_53.htm EXHIBIT 10.53
EXHIBIT 10.53
[BOEHRINGER
INGELHEIM LOGO]
| Boehringer Ingelheim International GmbH - 55216 Ingelheim am Rhein InterMune Pharmaceuticals 3280 Bayshore Blvd Brisbane, CA 94005 U.S.A. | Boehringer Ingelheim International GmbH | |
28 May 2002 | ||
Development and Marketing Agreement dated March 23, 2001 (Agreement) | Our reference CD Dr.Mi-mw | |
Dear Sirs | Dr. David Mitchard Phone +49/61 32/77-34 08 Fax +49/61 32/77-35 83 E-Mail ***@*** | |
Words and expressions defined or interpreted in the Agreement shall have the same meanings and interpretations when used in this letter. We propose the following changes to the Agreement: | Binger Strasse 173 55216 Ingelheim am Rhein Germany Phone +49/61 32/77-0 Fax +49/61 32/72-0 www.boehringer-ingelheim.com |
- 1.10
- The definition Field is extended to include liver fibrosis (lf).
- 1.22
- The definition New Indications is extended to include lf.
- 1.25
- The definition Protocols is extended to include the clinical protocol
entitled
"GILF-001"
which InterMune sent to BII with a letter dated April 25, 2002.
If you agree with the above, please signify your acceptance by signing and
returning one original of this letter.
| Yours faithfully BOEHRINGER INGELHEIM INTERNATIONAL GmbH ppa. /s/ Dr. Mitchard Jesse Dr. Mitchard Jesse | Accepted for and on behalf of InterMune, Inc. /s/ John J. Wulf John J. Wulf by: Sr. V.P. of Corporate Development Date: June 5, 2002 | Board of Managing Directors Prof. Dr Dr h.c. Rolf Krebs (Chairman) Dr Alessandro Banchi Dr Dr Andreas Barner Dr Hans-Jürgen Leuchs Prof. Dr Marbod Muff Seat Ingelheim am Rhein Commercial Register Bingen HR B 1063 Deutsche Bank AG BLZ 550 700 40 Account No. 0122 580 Swift: DEUTDE5M |
